NASDAQ:AEZS Aeterna Zentaris (AEZS) Stock Forecast, Price & News $2.47 -0.02 (-0.80%) (As of 09/26/2023 ET) Add Compare Share Share Today's Range$2.44▼$2.4850-Day Range$2.44▼$3.1952-Week Range$2.32▼$4.40Volume6,753 shsAverage Volume12,081 shsMarket Capitalization$11.99 millionP/E RatioN/ADividend YieldN/APrice Target$28.00 ProfileProfileAnalyst RatingsChartCompetitorsEarningsFinancialsInstitutional OwnershipHeadlinesOptions ChainSEC FilingsShort InterestSocial MediaProfileAnalyst RatingsChartCompetitorsEarningsFinancialsInstitutional OwnershipHeadlinesOptions ChainSEC FilingsShort InterestSocial Media Aeterna Zentaris MarketRank™ ForecastAnalyst RatingBuy3.00 Rating ScoreUpside/Downside1,033.6% Upside$28.00 Price TargetShort InterestHealthy1.30% of Float Sold ShortDividend StrengthN/ASustainabilityN/ANews Sentiment0.00Based on 3 Articles This WeekInsider TradingN/AProj. Earnings GrowthDecreasingFrom ($2.67) to ($3.15) Per ShareSee Full Details Hide Full Details Overall MarketRank™MarketRank is calculated as an average of available category scores, with extra weight given to analysis and valuation.1.70 out of 5 starsMedical Sector850th out of 964 stocksPharmaceutical Preparations Industry389th out of 438 stocks 3.5 Analyst's Opinion Consensus RatingAeterna Zentaris has received a consensus rating of Buy. The company's average rating score is 3.00, and is based on 1 buy rating, no hold ratings, and no sell ratings.Price Target Upside/DownsideAccording to analysts' consensus price target of $28.00, Aeterna Zentaris has a forecasted upside of 1,033.6% from its current price of $2.47.Amount of Analyst CoverageAeterna Zentaris has only been the subject of 1 research reports in the past 90 days. Previous Next 3.0 Short Interest Percentage of Shares Shorted1.30% of the float of Aeterna Zentaris has been sold short.Short Interest Ratio / Days to CoverAeterna Zentaris has a short interest ratio ("days to cover") of 6.7.Change versus previous monthShort interest in Aeterna Zentaris has recently decreased by 0.94%, indicating that investor sentiment is improving. Previous Next 0.0 Dividend Strength Dividend YieldAeterna Zentaris does not currently pay a dividend.Dividend GrowthAeterna Zentaris does not have a long track record of dividend growth. Previous Next N/A Sustainability and ESG Overall ESG (Environmental, Social, and Governance) ScoreThere is no current Upright™ data available for AEZS. Previous Next 0.6 News and Social Media Coverage News Coverage This WeekMarketBeat has tracked 3 news articles for Aeterna Zentaris this week, compared to 0 articles on an average week.MarketBeat Follows2 people have added Aeterna Zentaris to their MarketBeat watchlist in the last 30 days. This is an increase of 100% compared to the previous 30 days. Previous Next 0.0 Company Ownership Insider Buying vs. Insider SellingIn the past three months, Aeterna Zentaris insiders have not sold or bought any company stock.Percentage Held by InsidersOnly 0.10% of the stock of Aeterna Zentaris is held by insiders.Percentage Held by InstitutionsOnly 0.57% of the stock of Aeterna Zentaris is held by institutions. Previous Next 0.6 Earnings and Valuation Earnings GrowthEarnings for Aeterna Zentaris are expected to decrease in the coming year, from ($2.67) to ($3.15) per share.Price to Earnings Ratio vs. the MarketThe P/E ratio of Aeterna Zentaris is -0.53, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Earnings Ratio vs. SectorThe P/E ratio of Aeterna Zentaris is -0.53, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Book Value per Share RatioAeterna Zentaris has a P/B Ratio of 0.34. P/B Ratios below 1 indicate that a company could be undervalued with respect to its assets and liabilities. Previous Next See Top Rated MarketRank™ Stocks Here About Aeterna Zentaris (NASDAQ:AEZS) StockAeterna Zentaris Inc., a specialty biopharmaceutical company, engages in developing and commercializing therapeutics and diagnostic tests. Its lead product is Macrilen (macimorelin), an orally available peptidomimetic ghrelin receptor (GHSR-1a) agonist that stimulates the secretion of growth hormone by binding to the GHSR-1a for the diagnosis of adult growth hormone deficiency and childhood-onset growth hormone deficiency, as well as oncology indications; and AEZS-150, a delayed clearance parathyroid hormonefusion polypeptide that is in preclinical trail for the treatment of hypoparathyroidism in adults. Aeterna Zentaris Inc. has a license agreement with University of Wuerzburg to research, develop, manufacture, and sell a potential COVID-19 vaccine; development, manufacture, and commercialization of the treatment for neuromyelitis optica spectrum disorder; and for pre-clinical development towards the potential treatment of Parkinson's disease. It also has a license agreement with Consilient Health Ltd. and NK MEDITECH Ltd. for the development and commercialization of macimorelin in the Republic of Korea; a distribution and commercialization agreement with Er-Kim Pharmaceuticals Bulgaria EOOD for the commercialization of macimorelin for the diagnosis of growth hormone deficiency in children and adults in Turkey and some non-European Union Balkan countries; as well as The University of Sheffield, the United Kingdom for the research, development, manufacture, and commercialization of parathyroid hormone fusion polypeptides for the treatment of primary hypoparathyroidism. Aeterna Zentaris Inc. was incorporated in 1990 and is headquartered in Summerville, South Carolina.Read More AEZS Price History View Price History Chart DataSkip Price History Chart 30 days | 90 days | 365 days | Advanced Chart AEZS Stock News HeadlinesSeptember 27, 2023 | americanbankingnews.comAeterna Zentaris (NASDAQ:AEZS) Earns Sell Rating from Analysts at StockNews.comSeptember 27, 2023 | americanbankingnews.comComparing Aeterna Zentaris (NASDAQ:AEZS) & Entrada Therapeutics (NASDAQ:TRDA)September 27, 2023 | Wall Street Fundamentals (Ad)The "Plug and Play" Model Putting Online Giants to ShameWhile e-commerce has been undergoing a turbulent time, a "simple" model has grown 4X faster than Amazon over the last 3 years. Applying this model to high-margin, recession-resistant businesses has shown to be profitable. But that's just the beginning of explaining the 400+% growth - and potential - of this "diamond in the rough."September 19, 2023 | americanbankingnews.comAeterna Zentaris (NASDAQ:AEZS) Receives New Coverage from Analysts at StockNews.comSeptember 12, 2023 | theglobeandmail.comClosing Bell: Aeterna Zentaris Inc down on Monday (AEZS)September 5, 2023 | finance.yahoo.comAeterna Zentaris to Present at the H.C. Wainwright 25th Annual Global Investment ConferenceAugust 15, 2023 | theglobeandmail.comClosing Bell: Aeterna Zentaris Inc flat on Tuesday (AEZS)August 10, 2023 | markets.businessinsider.comH.C. Wainwright Keeps Their Buy Rating on Aeterna Zentaris (AEZS)September 27, 2023 | Wall Street Fundamentals (Ad)The "Plug and Play" Model Putting Online Giants to ShameWhile e-commerce has been undergoing a turbulent time, a "simple" model has grown 4X faster than Amazon over the last 3 years. Applying this model to high-margin, recession-resistant businesses has shown to be profitable. But that's just the beginning of explaining the 400+% growth - and potential - of this "diamond in the rough."August 9, 2023 | finance.yahoo.comAeterna Zentaris (AEZS) Reports Q2 Loss, Tops Revenue EstimatesJuly 13, 2023 | finance.yahoo.comAeterna Zentaris Outlines Progress on Development Pipeline Programs and Provides Corporate UpdateJune 15, 2023 | finanznachrichten.deAeterna Zentaris Inc: Aeterna Zentaris Announces Results of Virtual 2023 Meeting of ShareholdersMay 26, 2023 | theglobeandmail.comClosing Bell: Aeterna Zentaris Inc down on Friday (AEZS)May 17, 2023 | theglobeandmail.comClosing Bell: Aeterna Zentaris Inc down on Tuesday (AEZS)May 15, 2023 | finance.yahoo.comAeterna Zentaris Announces Virtual 2023 Meeting of ShareholdersMay 12, 2023 | markets.businessinsider.comH.C. Wainwright Reaffirms Their Buy Rating on Aeterna Zentaris (AEZS)May 10, 2023 | finanznachrichten.deAeterna Zentaris Inc: Aeterna Zentaris Reports First Quarter 2023 Financial ResultsMay 9, 2023 | finance.yahoo.comAeterna Zentaris Reports First Quarter 2023 Financial ResultsApril 27, 2023 | theglobeandmail.comClosing Bell: Aeterna Zentaris Inc down on Wednesday (AEZS)April 6, 2023 | theglobeandmail.comClosing Bell: Aeterna Zentaris Inc up on Thursday (AEZS)April 6, 2023 | theglobeandmail.comClosing Bell: Aeterna Zentaris Inc up on Wednesday (AEZS)April 6, 2023 | finance.yahoo.comAeterna (AEZS) Falls 5% on US Sales Halt of Growth Hormone DrugApril 5, 2023 | finanznachrichten.deAeterna Zentaris Inc: Aeterna Zentaris Provides Update on Macrilen (Macimorelin), Reiterates Advancement of Pediatric DETECT TrialApril 5, 2023 | finance.yahoo.comAeterna Zentaris Provides Update on Macrilen® (Macimorelin), Reiterates Advancement of Pediatric DETECT TrialMarch 23, 2023 | finance.yahoo.comAeterna Zentaris (AEZS) Reports Q4 Loss, Tops Revenue EstimatesMarch 23, 2023 | financialpost.comAeterna Zentaris Reports Fourth Quarter and Full Year 2022 Financial ResultsMarch 16, 2023 | finance.yahoo.comPharmanovia to Market GHRYVELIN™ (Macimorelin) in the European Economic Area (EEA) and UK as Diagnostic Test for Growth Hormone Deficiency (GHD)See More Headlines Receive AEZS Stock News and Ratings via Email Sign-up to receive the latest news and ratings for Aeterna Zentaris and its competitors with MarketBeat's FREE daily newsletter. Email Address AEZS Company Calendar Last Earnings8/09/2023Today9/27/2023Next Earnings (Estimated)11/02/2023Fiscal Year End12/31/2023Get Stock AlertsIndustry, Sector and Symbol Stock ExchangeNASDAQ Industry Pharmaceutical preparations Sub-IndustryN/A SectorMedical Current SymbolNASDAQ:AEZS CUSIPN/A CIK1113423 Webwww.zentaris.com Phone(418) 652-8525Fax418-948-9191Employees11Year FoundedN/APrice Target and Rating Average Stock Price Forecast$28.00 High Stock Price Forecast$28.00 Low Stock Price Forecast$28.00 Forecasted Upside/Downside+1,033.6%Consensus RatingBuy Rating Score (0-4)3.00 Research Coverage1 Analysts Profitability EPS (Most Recent Fiscal Year)($4.66) Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/ANet Income$-22,730,000.00 Net Margins-259.71% Pretax Margin-259.71% Return on Equity-39.30% Return on Assets-25.94% Debt Debt-to-Equity RatioN/A Current Ratio11.26 Quick Ratio11.23 Sales & Book Value Annual Sales$8.72 million Price / Sales1.38 Cash FlowN/A Price / Cash FlowN/A Book Value$7.37 per share Price / Book0.34Miscellaneous Outstanding Shares4,856,000Free Float4,851,000Market Cap$11.99 million OptionableOptionable Beta1.35 Social Links 10 Best Cheap Stocks to Buy NowMarketBeat just released its list of 10 cheap stocks that have been overlooked by the market and may be seriously undervalued. Click the link below to see which companies made the list.Get This Free Report Key ExecutivesDr. Klaus Paulini Ph.D.Pres, CEO & Exec. DirectorMr. Giuliano La FrattaSr. VP of Fin. & CFODr. Michael Teifel Ph.D.Sr. VP of Non-Clinical Devel. & Chief Scientific OfficerDr. Nicola Ammer M.D.Chief Medical Officer & Sr. VP of Clinical Devel.Dr. Matthias GerlachSr. VP Manufacturing & Supply ChainKey CompetitorsMoleculin BiotechNASDAQ:MBRXTFF PharmaceuticalsNASDAQ:TFFPPasithea TherapeuticsNASDAQ:KTTALandos BiopharmaNASDAQ:LABPBiofronteraNASDAQ:BFRIView All Competitors AEZS Stock - Frequently Asked Questions Should I buy or sell Aeterna Zentaris stock right now? 1 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Aeterna Zentaris in the last twelve months. There are currently 1 buy rating for the stock. The consensus among Wall Street analysts is that investors should "buy" AEZS shares. View AEZS analyst ratings or view top-rated stocks. What is Aeterna Zentaris' stock price forecast for 2023? 1 equities research analysts have issued 12-month target prices for Aeterna Zentaris' stock. Their AEZS share price forecasts range from $28.00 to $28.00. On average, they expect the company's share price to reach $28.00 in the next twelve months. This suggests a possible upside of 1,033.6% from the stock's current price. View analysts price targets for AEZS or view top-rated stocks among Wall Street analysts. How have AEZS shares performed in 2023? Aeterna Zentaris' stock was trading at $3.18 at the beginning of the year. Since then, AEZS shares have decreased by 22.3% and is now trading at $2.47. View the best growth stocks for 2023 here. When is Aeterna Zentaris' next earnings date? The company is scheduled to release its next quarterly earnings announcement on Thursday, November 2nd 2023. View our AEZS earnings forecast. How were Aeterna Zentaris' earnings last quarter? Aeterna Zentaris Inc. (NASDAQ:AEZS) issued its quarterly earnings results on Wednesday, August, 9th. The biopharmaceutical company reported ($0.52) earnings per share (EPS) for the quarter, topping analysts' consensus estimates of ($0.87) by $0.35. The biopharmaceutical company had revenue of $2.25 million for the quarter, compared to analyst estimates of $1.10 million. Aeterna Zentaris had a negative net margin of 259.71% and a negative trailing twelve-month return on equity of 39.30%. When did Aeterna Zentaris' stock split? Aeterna Zentaris shares reverse split on Thursday, July 21st 2022. The 1-25 reverse split was announced on Thursday, July 21st 2022. The number of shares owned by shareholders was adjusted after the closing bell on Thursday, July 21st 2022. An investor that had 100 shares of stock prior to the reverse split would have 4 shares after the split. What other stocks do shareholders of Aeterna Zentaris own? Based on aggregate information from My MarketBeat watchlists, some companies that other Aeterna Zentaris investors own include Zosano Pharma (ZSAN), Pennsylvania Real Estate Investment Trust (PEI), CBL & Associates Properties (CBL), Gran Tierra Energy (GTE), CNBX Pharmaceuticals (CNBX), Matinas BioPharma (MTNB), ADMA Biologics (ADMA), Bionano Genomics (BNGO), Novan (NOVN) and Washington Prime Group (WPG). What is Aeterna Zentaris' stock symbol? Aeterna Zentaris trades on the NASDAQ under the ticker symbol "AEZS." How do I buy shares of Aeterna Zentaris? Shares of AEZS stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab. Compare Top Brokerages Here. What is Aeterna Zentaris' stock price today? One share of AEZS stock can currently be purchased for approximately $2.47. How much money does Aeterna Zentaris make? Aeterna Zentaris (NASDAQ:AEZS) has a market capitalization of $11.99 million and generates $8.72 million in revenue each year. The biopharmaceutical company earns $-22,730,000.00 in net income (profit) each year or ($4.66) on an earnings per share basis. How can I contact Aeterna Zentaris? Aeterna Zentaris' mailing address is 315 Sigma Drive South Carolina, Summerville SC, 29486. The official website for the company is www.zentaris.com. The biopharmaceutical company can be reached via phone at (418) 652-8525, via email at ir@aezsinc.com, or via fax at 418-948-9191. This page (NASDAQ:AEZS) was last updated on 9/27/2023 by MarketBeat.com Staff Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Aeterna Zentaris Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Get 30 Days of MarketBeat All Access Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools: Best-in-Class Portfolio Monitoring View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio. Stock Ideas and Recommendations Get daily stock ideas from top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report. Advanced Stock Screeners and Research Tools Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis. Start Your 30-Day Free Trial Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Your Password: or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Choose a Password: Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.